SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO) Files An 8-K Regulation FD DisclosureItem 7.01
| Item 7.01 | Financial Statements and Exhibits. |
(d) Exhibits
SANGAMO THERAPEUTICS, INC ExhibitEX-99.1 2 d522217dex991.htm EX-99.1 EX-99.1 J.P. Morgan 36th Annual Healthcare Conference Dr. Sandy Macrae CEO January 10,…To view the full exhibit click here
About SANGAMO THERAPEUTICS, INC. (NASDAQ:SGMO)
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has developed technologies available for gene-based therapies. Its product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Its zinc finger nuclease (ZFN) in vivo genome editing approach is being evaluated in Phase I/II clinical trials to treat hemophilia B and lysosomal storage disorders mucopolysaccharidosis (MPS) I and MPS II. It is also conducting a Phase I/II clinical trial to evaluate its adeno associated virus (AAV) complementary deoxyribonucleic acid (cDNA) human Factor 8 gene therapy approach, SB-525, to treat hemophilia A. It has investigational new drug application for SB-525. It is also developing ZFN-mediated genome editing-based therapies for blood disorders and cancer.
